sec filing - novogen yale uni joint venture , page-18

Yes it certainly is great news, Professor Gil Mor has been part of what Novogen have been doing for years, Phenoxodiol was one of his early dealings with Novogen.

So we now know who the joint venture partner is and only for one target, ovarian cancer, we also now know what the new delivery system is as well this new delivery system is aimed straight at ovarian cancer to deliver the Trilexium variant, this may mean that ovarian cancer will not mean a death sentence in many cases like it has in the past, it will not be the killer it once was if they get this right.

A variant of Trilexium has been identified as a powerful killer of ovarian cancer stem cells and is being packed into a delivery system specially designed by Professor Mor’s laboratory that is to be given intra-peritoneally (the abdominal cavity) where it seeks out ovarian cancer cells.”
“When anti-cancer drugs are injected intravenously, usually only 3% or so of the drug actually reaches the tumor.
With this delivery system, virtually all injected drug reaches the tumor, thereby ensuring maximum anti-cancer effect.”